Key Market Indicators
British Pharmaceutical R&D Expenditure Poised for Modest Growth LONDON — The United Kingdom's pharmaceutical research and development expenditure is projected to reach approximately $669 million in purchasing power parity (PPP) by 2028. This marks a slight increase from the current $662 million in 2023, reflecting an average annual growth rate of 0.1%. Since 2012, the British pharmaceutical sector has experienced a consistent, albeit modest, annual increase of 0.1% in R&D spending. In the global ranking for 2023, the UK holds the seventh position. Italy has surpassed the UK, also recording an expenditure of $662 million PPP. China, Germany, and South Korea continue to lead the field, occupying the second, third, and fourth spots, respectively.
